An unexpected departure at the top is overshadowing a positive quarterly update for AngioDynamics.
AngioDynamics shows how product mix shifts toward higher-margin Med Tech platforms are quietly reshaping earnings power ...
AngioDynamics (NASDAQ:ANGO) executives used a conference presentation hosted by J.P. Morgan to outline the company’s ...
AngioDynamics Corp. intends to cut 54 out of 265 jobs from its Glens Falls and Queensbury facilities.
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, ...
AngioDynamics (ANGO) has been on a downward spiral lately with significant selling pressure. After declining 25% over the ...
Peer-reviewed findings demonstrate high disease control and quality-of-life preservation, supporting shift toward focal therapy in prostate treatment “The publication of the PRESERVE study in European ...
CEO Jim Clemmer highlighted strong Q3 performance with total revenue reaching $72 million, reflecting over 9% year-over-year growth. MedTech revenue grew by 22%, with continued success across ...
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options ...
AngioDynamics has announced it has received FDA clearance for a new peripherally inserted central catheter, according to a news release. The company’s BioFlo peripherally inserted central catheters ...
Shares of AngioDynamics (NASDAQ: ANGO) were crashing 17.1% lower as of 10:43 a.m. ET on Thursday. The steep sell-off came after the medical technology company announced its fiscal 2025 first-quarter ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results